Wells Fargo Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal upgraded Neurocrine Biosciences (NBIX) from Equal-Weight to Overweight and increased the price target from $140 to $170.
April 24, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences was upgraded by Wells Fargo from Equal-Weight to Overweight, with a price target increase from $140 to $170.
Upgrades by major financial institutions like Wells Fargo generally lead to positive short-term price movements. The significant increase in the price target reflects a strong confidence in the company's future performance, likely influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100